From: Evaluation of myosin VI, E-cadherin and beta-catenin immunostaining in renal cell carcinoma
 | Membranous E-cadherin | Nuclear E-cadherin | ||
---|---|---|---|---|
 | positive | negative | positive | negative |
Tumour class (T) | Â | Â | Â | Â |
1 (n = 72) | 7 (10%) | 65 (90%) | 34 (47%) | 38 (53%) |
2 (n = 11) | 1 (9%) | 10 (91%) | 5 (45%) | 6 (55%) |
3 (n = 59) | 5 (8%) | 54 (92%) | 17 (29%) | 42 (71%) |
4 (n = 6) | 1 (17%) | 5 (83%) | 3 (50%) | 3 (50%) |
Stage | Â | Â | Â | Â |
I (n = 67) | 6 (9%) | 61 (91%) | 32 (48%) | 35 (52%) |
II (n = 11) | 1 (9%) | 10 (91%) | 5 (45%) | 6 (55%) |
III (n = 51) | 5 (10%) | 46 (90%) | 13 (25%) | 38 (75%) |
IV (n = 19) | 2 (10%) | 17 (90%) | 9 (47%) | 10 (53%) |
Grade | Â | Â | Â | Â |
I (n = 5) | 0 (0%) | 5 (100%) | 1 (20%) | 4 (80%) |
II (n = 81) | 4 (5%) | 77 (95%) | 38 (47%) | 43 (53%) |
III (n = 38) | 5 (13%) | 33 (87%) | 14 (37%) | 24 (63%) |
IV (n = 22) | 3 (14%) | 19 (86%) | 6 (27%) | 16 (73%) |
Histological subtype of RCC | Â | Â | Â | Â |
clear cell (n = 131) | 8 (6%) | 123 (94%) | 52 (40%) | 79 (60%) |
papillary (n = 10) | 0 (0%) | 10 (100%) | 6 (60%) | 4 (40%) |
chromophobic (n = 5) | 4 (80%) | 1 (20%) | 1 (20%) | 4 (80%) |
undifferentiated (n = 2) | 2 (100%) | 0 (0%) | 0 (0%) | 2 (100%) |